Zymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Ratings for Zymeworks (NASDAQ:ZYME) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.4, a high estimate of $16.00, and a low estimate of $10.00. This current average has decreased by 2.75% from the previous average price target of $12.75.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Zymeworks by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Maintains | Neutral | $10.00 | - |
| Yigal Nochomovitz | Citigroup | Lowers | Buy | $16.00 | $17.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $12.00 | $14.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $14.00 | $12.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Neutral | $10.00 | $8.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zymeworks. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zymeworks compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Zymeworks's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Zymeworks's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Zymeworks analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Zymeworks's Background
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Zymeworks's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -71.81%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zymeworks's net margin excels beyond industry benchmarks, reaching -315.58%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zymeworks's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -7.01%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Zymeworks's ROA stands out, surpassing industry averages. With an impressive ROA of -5.58%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Zymeworks's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.